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Abstract The prolyl isomerase activity of cyclophilins is 
traditionally measured by an assay in which prolyl cisltrans 
isomerization in a chromogenic tetrapeptide is coupled with its 
isomer-specific cleavage by chymotrypsin. Two variants of 
mitochondrial cyclophilin with substitutions in the presumed 
active site (R73A and H144Q) are inactive in the protease-
coupled assay, but show almost wild-type activity in an assay that 
is based on the catalysis of a proline-limited protein folding 
reaction. This prolyl isomerase assay is preferable, both because 
coupling with proteolysis is avoided and because an intact protein 
instead of a short peptide is used as a substrate. Possibly, some 
earlier conclusions about the catalytic mechanism and the 
involvement of the prolyl isomerase activity in the cellular 
function of immunophilins may need reevaluation. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Cyclophilins are ubiquitous proteins that are enzymatically 
active as prolyl isomerases and bind with high affinity to the 
immunosuppressive drug cyclosporin A (CsA). The first cyclo-
philin (cyclophilin A) was co-discovered in 1984 by Fischer 
and coworkers [1], who developed a protease-coupled assay to 
identify enzymes that might catalyze proline-limited protein 
folding reactions1, and by Handschumacher and coworkers 
[2], who employed affinity chromatography to identify a re-
ceptor for CsA. In 1989 it became clear that the proteins 
identified by the two groups were identical [3,4], and it was 
immediately speculated that the function of cyclophilins in 
immunosuppression might be linked to prolyl isomerase ac-
tivity. Subsequent work, however, indicated that this is not 
the case. First, yeast mutants lacking cyclophilin A are viable 
and cyclosporin resistant, indicating that cyclophilin is not 
essential, and both the protein and the drug are required for 
drug action [5,6]. Second, the binary complex between CsA 
and cyclophilin was found to bind to and inhibit the phos-
phatase calcineurin [7,8]. A similar mechanism is used by FK 
*Corresponding author. Fax: (49) (921) 553661. 
E-mail: franz-xaver-schmid@uni-bayreuth.de 
Abbreviations: RNase Tl, ribonuclease Tl; RCM-(S54G/P55N)-
RNase Tl, disulfide-reduced and S-carboxymethylated form of a 
variant of RNase Tl with Ser54 and Pro55 replaced by Gly and Asn, 
respectively; Cpr3, mitochondrial cyclophilin of Saccharomyces 
cerevisiae; GdmCl, guanidinium chloride 
1 To facilitate reading we use the expression 'proline-limited' protein 
folding for a folding reaction that involves the isomerization of a Xaa-
Pro peptide bond as the rate-limiting step. 
506, another immunosuppressive drug that also inhibits calci-
neurin when bound to its receptor FKBP, which, surprisingly, 
is also a prolyl isomerase [9-11]. 
Cyclophilins are probably involved in many processes in the 
cell [12-20]. Whether the prolyl isomerase activity of a partic-
ular cyclophilin is involved in these functions is usually exam-
ined by comparing the effects of site-directed mutations on the 
in vivo function and on the in vitro prolyl isomerase activity 
towards a tetrapeptide in the protease-coupled assay. Several 
mutations that apparently impaired the prolyl isomerase ac-
tivity in vitro seemed to affect the cellular functions of cyclo-
philins in some processes but not in others. This led to con-
flicting views about the role of this enzymatic activity for the 
function of cyclophilins in vivo [21-24]. 
The conformational specificity of a protease (usually chy-
motrypsin) for d\\-trans peptides is used to follow prolyl iso-
merization in the standard prolyl isomerase assay. The pro-
tease must be present at high concentration in these assays, 
and therefore a mutation that increases the protease suscept-
ibility of a cyclophilin would erroneously be classified as in-
activating. We therefore employed an alternative assay for 
PPI activity, which avoids coupling with proteolysis and 
uses a protein instead of a short peptide as the substrate. In 
this assay the catalysis of a folding reaction is measured, 
which is limited in rate by prolyl cisltrans isomerization. 
We show here that based on the protease-coupled assay two 
mutations at the presumed active site of cyclophilin have 
falsely been classified as inactivating. In fact, the prolyl iso-
merase activity is retained in these variants, and they catalyze 
proline-limited protein folding almost as efficiently as the 
wild-type protein. This indicates that the results from the tra-
ditional protease-linked prolyl isomerase assay may have led 
to invalid conclusions about the enzymatic mechanism and 
the in vivo function of the prolyl isomerase activity of cyclo-
philins. 
2. Materials and methods 
2.1. Materials 
(S54G,P55N)-RNase Tl2 was purified and carboxymethylated as 
described [25]. The concentrations of RCM-(S54G/P55N)-RNase Tl 
were determined spectrophotometrically by using an absorption coef-
ficient of E278 = 21060 IVr
1 cm"1 [26]. 
2.2. Expression and purification of wild-type and mutated forms of the 
yeast Cpr3 protein 
The R73A and H144Q mutations in the mitochondrial cyclophilin 
Cpr3 of yeast are analogous to the R55A and H126Q mutations in 
human cyclophilin A, respectively [21]. They were engineered and 
cloned in the bacterial His6-expression plasmid pTrcHisB (Invitro-
gen), as described (Dolinski et al., submitted). The wild-type and 
the mutant proteins lack the mitochondrial leader sequence but carry 
a hexahistidine tag at the amino-terminus. 
Cpr3-producing cells were harvested by centrifugation (lOOOOXg, 
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20 min, 4°C) and lysed by a 1-h incubation at room temperature in 50 
mM Tris-HCl, pH 7.9, containing 6.0 M GdmCl, 0.25 M NaCl and 5 
mM imidazole (5 ml per gram of cell pellet), followed by sonication. 
The lysate was cleared by centrifugation (lOOOOXg, 20 min, 4°C). The 
supernatant containing the denatured protein was bound to a Ni-
NTA Superflow column (Qiagen, Hilden, Germany) and washed 
with 300 ml of the lysis buffer. To refold the proteins a linear gradient 
from 6.0 to 0 M GdmCL in 180 ml 50 mM Tris-HCl, pH 7.9, 10 mM 
imidazole was applied over a period of 90 min at 4°C. Then the 
refolded protein was eluted by a linear gradient from 10 to 100 mM 
imidazole in 100 ml of 50 mM Tris-HCl, pH 7.9. Protein-containing 
fractions were assayed for prolyl isomerase activity in the protease-
coupled and in the protein folding assay, pooled, and concentrated by 
ultrafiltration (Ultrafree-15, Millipore Corp.). The Cpr3 proteins 
showed purities higher than 95% as judged by denaturing gel electro-
phoresis and Coomassie staining. 
2.3. Measurements of prolyl isomerase activity in the peptide assays 
In the first procedure the chromogenic peptide succinyl-Ala-Leu-
Pro-Phe-4-nitroanilide in a coupled assay with chymotrypsin was 
used [1]. 910 nl of 0.1 M Tris-HCl (pH 8.0) and 50 ill of a 600 uM 
solution of a-chymotrypsin (Boehringer-Mannheim, Germany) were 
mixed in the spectrophotometer cell and preincubated at 15°C for 10 
min. Then 30 ul of the cyclophilin solution to be assayed was added 
and after 5 min the assay was initiated by adding 10 ul of a 7.8 mM 
solution of the assay peptide in trifluorethanol that additionally con-
tained 0.45 M LiCl [27]. The cis-* trans isomerization of the Leu-Pro 
bond, coupled with the chymotryptic cleavage of the trans peptide was 
followed by the increase in absorbance at 390 nm in a HP 8452 diode 
array spectrophotometer. Monoexponential functions were fit to the 
progress curves, and the activity was calculated from the observed 
rate constants [1]. 
In the protease-free assay succinyl-Ala-Phe-Pro-Phe-4-nitroanilide 
was used as a substrate. 955 ul 0.1 M Tris-HCl (pH 8.0) and 30 ul 
of the Cpr3 enzyme under investigation were incubated in the spec-
trophotometer cell for 10 min. The assay was started by adding 15 ul 
of a 7.8 mM solution of the assay peptide in trifluoroethanol/0.45 M 
LiCl. The final peptide concentration was 120 uM. The cisltrans iso-
merization of the Phe-Pro peptide bond was followed by the small 
decrease of the absorbance at 330 nm of the nitroanilide moiety (G. 
Fischer and coworkers, personal communication). 
2.4. Folding experiments 
RCM-(S54G/P55N)-RNase Tl was unfolded by incubating the pro-
tein in 0.1 M Tris-HCl, pH 8.0 at 15°C for at least 1 h. Refolding at 
15°C was initiated by a 40-fold dilution of the unfolded protein to 
final conditions of 2.0 M NaCl and the desired concentrations of the 
wild type protein and the variants of Cpr3 in the same buffer. The 
folding reaction was followed by the increase in protein fluorescence 
at 320 nm (10 nm band width) after excitation at 268 nm (1.5 nm 
band width). The small contribution of the Cpr3 proteins to the fluo-
rescence was subtracted from the measured values in the individual 
experiments. At 2.0 M NaCl slow folding was a monoexponential 
process and its rate constant was determined by using the program 
Grafit 3.0 (Erithacus Software, Staines, UK). Fluorescence was meas-
ured in a Hitachi F4010 fluorescence spectrophotometer. 
3. Results and discussion 
3.1. Cpr3 mutant cyclophilins are inactive when measured 
by the protease-coupled assay 
The standard assay for prolyl isomerase activity [1] is based 
on the conformational specificity of chymotrypsin. This pro-
tease cleaves the 4-nitroanilide moiety from succinyl-Ala-Xaa-
Pro-Phe-4-nitroanilides only when the Xaa-Pro peptide bond 
is in the trans conformation. Under our assay conditions 
about 60% of the substrate molecules are trans and are 
cleaved within the dead time of manual mixing by the 30 
u,M chymotrypsin present in the assay solution. The hydrol-
ysis of the remaining 40% cis peptide is slow, limited in rate 
by the cisltrans conversion at the Xaa-Pro bond of the 
peptide. This assay is very sensitive. Prolyl isomerases can 
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Fig. 1. Activity of wild-type and mutant Cpr3 proteins in the pro-
tease coupled prolyl isomerase assay. (A) Time course of the cis-* 
trans isomerization of the Leu-Pro peptide bond in the assay pep-
tide succinyl-Ala-Leu-Pro-Phe-4-nitroanilide, as measured by the 
increase in ^390 after the coupled hydrolysis by chymotrypsin. The 
uncatalyzed cisltrans isomerization in the absence of Cpr3 is 
shown by the lower continuous line, isomerization catalyzed by 31 
nM wild-type Cpr3 by the upper continuous line, the isomerizations 
in the presence of 100 nM R73A variant and 100 nM H144Q var-
iant are shown by the dashed and dash-dotted lines, respectively. 
(B) The measured prolyl isomerase activities as a function of the 
concentration of wild-type Cpr3 (□), the H144Q (o) and the R73A 
( A ) variants. The activity is shown as klkg, where k and kQ are the 
rate constants of isomerization in the presence and in the absence 
of these proteins, respectively. The activities were measured at 15°C 
described in the Methods (see Section 2). 
be detected at nanomolar concentration, and many prolyl 
isomerases were discovered using this assay [14,28]. 
To test the reliability of the protease-coupled prolyl isomer-
ase assay we employed the mitochondrial cyclophilin Cpr3 
from Saccharomyces cerevisiae and its R73A and H144Q var-
iants. This cyclophilin is essential for mitochondrial metabo-
lism at elevated temperature [15], and it is involved in the 
folding of proteins imported into mitochondria [17,18] (Do-
linski et al., submitted). The residues equivalent to R73 and 
H144 in human cyclophilin (R55 and H126) are in the pre-
sumed active site [29-33], and the respective mutat ions in the 
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human protein (R55A and H126Q) led to an almost complete 
loss of the prolyl isomerase activity as measured by the pro-
tease-coupled assay [21]. We observed such a loss of activity in 
the protease-coupled assay also for the R73A and H144Q 
variants of the yeast Cpr3 enzyme (Fig. 1). The wild-type 
protein showed a high activity, and the isomerization of the 
assay peptide was accelerated 5-fold in the presence of 31 nM 
Cpr3 protein (Fig. 1A). In contrast, when 100 nM of the 
R73A variant or 100 nM of the H144Q variant were added, 
only marginal accelerations of prolyl isomerization could be 
detected (Fig. 1A). The very low activity of the mutant en-
zymes in the protease-coupled assay was confirmed when the 
Cpr3 concentration was varied (Fig. IB). 
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Fig. 2. Catalysis of RCM-(S54G/P55N)-RNase Tl refolding. (A) Ki-
netics of refolding of 0.35 uM RCM-(S54G/P55N)-RNase Tl in the 
absence (lowest curve) and in the presence of 10, 20, and 50 nM 
wild-type and mutant Cpr3. The folding kinetics in the presence of 
the wild-type protein are shown by the continuous line, the folding 
reactions in the presence of the H144Q variant and the R73A var-
iant are shown by the dashed and dotted lines, respectively. (B) 
Measured catalytic activities in folding as a function of the concen-
tration of wild-type Cpr3 (□), the H144Q (o) and the R73A ( A ) 
variants. The activity is shown as k/kg, where k and ka are the rate 
constants of folding of RCM-(S54G/P55N)-RNase Tl in the pres-
ence and in the absence of the Cpr3 proteins, respectively. The fold-
ing kinetics were measured at 15°C in 0.1 M Tris-HCl, 2.0 M NaCl 
by the increase in fluorescence at 320 nm. 
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Fig. 3. Activity of wild-type and mutant Cpr3 proteins in the pro-
tease-free prolyl isomerase assay. The cisltrans isomerization of the 
Phe-Pro peptide bond in the assay peptide succinyl-Ala-Phe-Pro-
Phe-4-nitroanilide was measured by the decrease in A330 in the ab-
sence of a protease. The measured prolyl isomerase activities are 
shown as a function of the concentration of wild-type Cpr3 (□), the 
H144Q (O) and the R73A ( A ) variants. The activity is shown as kl 
ko, where k and kg are the rate constants of isomerization in the 
presence and in the absence of these proteins, respectively. The ac-
tivities were measured at 15°C as described in the Methods (see Sec-
tion 2). 
3.2. Mutated Cpr3 cyclophilins are active when measured by a 
protein folding assay 
To measure the activities of the wild-type and the two mu-
tant Cpr3 enzymes in a proline-limited protein folding reac-
tion, we used a reduced and carboxymethylated variant of 
ribonuclease Tl , RCM-(S54G/P55N)-RNase Tl,as a substrate 
protein. Native wild-type RNase Tl contains two cis prolyl 
bonds at Pro39 and Pro55, and their isomerizations are the 
rate-limiting steps in the folding of RNase Tl . The (S54G/ 
P55N)-RNase Tl variant contains only a single cys prolyl 
bond (Tyr38-Pro39). Its folding mechanism is therefore partic-
ularly simple, and it is well characterized in molecular detail 
[34,35]. Moreover, in the disulfide-reduced and carboxymeth-
ylated RCM form it is an excellent substrate for a wide range 
of prolyl isomerases [36]. 85% of all unfolded molecules of 
RCM-(S54G/P55N)-RNase Tl contain an incorrect trans 
Pro39 and fold in a monophasic and reversible reaction, which 
is controlled in its rate by the slow trans-cis isomerization of 
the Tyr38-Pro39 prolyl peptide bond. In the absence of a cata-
lyst this folding reaction shows a time constant of 570 s (Fig. 
2A). When 50 nM wild-type Cpr3 enzyme was added folding 
was a 22-fold accelerated and the time constant decreased to 
26 s. Comparable acceleration factors of 14 and 16 were ob-
served when 50 nM of the R73A or the H144Q mutant en-
zymes was added (Fig. 2A). In all three cases the acceleration 
factors were approximately linear functions of the Cpr3 en-
zyme concentration as expected for an enzyme-catalyzed re-
action (Fig. 2B). The comparison of the slopes in Fig. 2B 
reveals that the R73A and H144Q variants are in fact 65% 
and 75%, respectively, as active as the wild-type protein when 
assayed with the protein substrate RCM-(S54G/P55N)-RNase 
Tl . 
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Fig. 4. Inactivation of the Cpr3 mutant proteins in the protease-
coupled assay. The kinetics of the uncatalyzed cis-* trans isomeriza-
tion of the Leu-Pro peptide bond in the assay peptide succinyl-Ala-
Leu-Pro-Phe-4-nitroanilide, as measured by the increase in 3^90 is 
shown by the lowest line. In separate experiments 100 nM of wild-
type Cpr3 (upper continuous line), of the R73A mutant (second line 
from the bottom), or the H144Q mutant (third line), were added 
after 40 s into the ongoing assay (as indicated by the vertical line). 
Isomerization-coupled peptide hydrolysis was measured at 15°C as 
described in the Methods (see Section 2). 
3.3. The R73A and H144Q mutants show partial activity in a 
protease-free peptide-based assay 
Recently Fischer and coworkers developed a variant of the 
peptide-based assay for prolyl isomerase activity, which 
avoids the coupling with isomer-specific proteolysis (G. Fisch-
er and coworkers, submitted). In this assay the slight decrease 
in absorbance at 330 nm upon cis■-> trans isomerization is 
used in combination with a jump in the solvent conditions 
to monitor the kinetics of Phe-Pro isomerization in the un-
cleaved assay peptide. Because of the small change in signal 
the sensitivity of the assay is limited, but it indicates that the 
two Cpr3 mutants show roughly 20% of the prolyl isomerase 
activity of the wild-type protein (Fig. 3). That the mutations 
affect the activity towards a peptide more strongly than to-
wards a protein may be attributable to additional binding 
interactions that are available for long but not for short sub-
strates. 
3.4. The R73A and H144Q mutations sensitize Cpr3 to 
degradation by chymotrypsin 
The simplest explanation for the apparent lack of prolyl 
isomerase activity in the protease-coupled assay is that the 
mutations increased the protease sensitivity of the Cpr3 pro-
tein. When the time of pre-incubation of the H144Q mutant 
with the protease is progressively decreased from 10 min as in 
the standard assay procedure to as short as 10 s, a marginal 
but significant prolyl isomerase activity is observed (data not 
shown). 
The rapid degradation during the protease-coupled assay is 
clearly revealed in an experiment in which uncatalyzed prolyl 
isomerization in the peptide is initiated at time zero in the 
absence of a prolyl isomerase (Fig. 4). When after 40 s 100 
nM of the wild-type protein is added, isomerization is strongly 
accelerated. The slope of the absorbance curve in Fig. 4 in-
creases abruptly, and the final absorbance is reached after a 
further 50 s. When instead 100 nM of the H144Q mutant is 
added after 40 s, the isomerization rate also increases imme-
diately, but to a smaller extent than in the presence of 100 nM 
wild-type Cpr3 enzyme, and, moreover, after about a further 
100 s it returns to the rate of the uncatalyzed reaction, be-
cause the protein is inactivated by the protease within this 
short period of time. Very similar results were obtained with 
the R73A mutant enzyme (Fig. 4). 
Together, our results suggest that the two mutations have 
only a marginal effect on the prolyl isomerase activity of the 
Cpr3 enzyme towards protein substrates. The activity towards 
a tetrapeptide is significantly reduced, and, moreover, this 
activity is hardly detectable in the standard protease-coupled 
assay, because unlike the wild-type protein the mutated pro-
teins are rapidly destroyed by chymotrypsin at the onset of 
the assay. 
4. Conclusions 
The protease-coupled assay for prolyl isomerase activity 
provides meaningful results only for proteins that are resistant 
to proteolytic cleavage during the assay, which typically takes 
1-5 min. The protease resistance of newly discovered prolyl 
isomerases or of mutated forms was not examined routinely in 
the past, and therefore it is possible that some of the muta-
tions in cyclophilins that were reported to inactivate these 
proteins instead destabilized them such that they are rapidly 
degraded by the helper protease in the assay. Several non-
proteolytic assays based on modified peptides have been de-
veloped, but are not used widely, due to their inherent com-
plexity [37-39]. 
The catalysis of proline-limited protein folding provides a 
superior assay for prolyl isomerase activity because an intact 
protein (instead of a short peptide) is employed as substrate, 
and because coupling with proteolysis is avoided. Folding 
protein chains or native proteins with exposed prolyl bonds 
may be the natural substrates of prolyl isomerases, and there-
fore the folding assay reflects the cellular functions of these 
enzymes more closely. When using the protease-coupled pep-
tide assay the proteolytic susceptibility of the prolyl isomerase 
under investigation must be examined (as suggested already 
when the first prolyl isomerase was discovered [1]). 
Our results on two variants of a yeast mitochondrial cyclo-
philin indicate that some mutations in prolyl isomerases may 
have erroneously been classified as inactivating. The respective 
conclusions about the mechanism of catalyzed prolyl isomer-
ization and about the involvement of the prolyl isomerase 
activity in the cellular function of immumophilins may there-
fore need reevaluation. It is clear that mutations, even when 
they are located at a presumed active site, may nevertheless 
impair the in vitro or in vivo function of a protein not because 
a catalytic residue is changed, but indirectly because the pro-
tein is destabilized or sensitized for proteolytic degradation by 
the mutation. 
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